Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles Sells 43,459 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles sold 43,459 shares of the firm’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $11.95, for a total transaction of $519,335.05. Following the completion of the transaction, the chief executive officer now directly owns 6,065,772 shares in the company, valued at approximately $72,485,975.40. This represents a 0.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Patrick Miles also recently made the following trade(s):

• On Wednesday, January 29th, Patrick Miles sold 50,000 shares of Alphatec stock. The stock was sold at an average price of $12.03, for a total transaction of $601,500.00.
• On Tuesday, January 21st, Patrick Miles sold 6,687 shares of Alphatec stock. The shares were sold at an average price of $12.00, for a total transaction of $80,244.00.

Alphatec Price Performance

Alphatec stock opened at $11.36 on Friday. The company has a market capitalization of $1.61 billion, a PE ratio of -8.88 and a beta of 1.43. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The stock has a 50-day moving average price of $10.26 and a two-hundred day moving average price of $8.13. Alphatec Holdings, Inc. has a 12 month low of $4.88 and a 12 month high of $17.34.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ATEC shares. Barclays lifted their price target on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, January 22nd. Needham & Company LLC lifted their target price on Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Alphatec in a report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.56.

Institutional Investors Weigh In On Alphatec

Hedge funds have recently added to or reduced their stakes in the business. State Street Corp increased its position in Alphatec by 10.1% in the 3rd quarter. State Street Corp now owns 3,138,960 shares of the medical technology company’s stock valued at $17,453,000 after acquiring an additional 287,350 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of Alphatec by 11.3% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock worth $16,280,000 after purchasing an additional 297,850 shares during the last quarter. Royce & Associates LP increased its holdings in Alphatec by 15.9% in the third quarter. Royce & Associates LP now owns 1,212,286 shares of the medical technology company’s stock valued at $6,740,000 after purchasing an additional 165,954 shares during the period. New York State Common Retirement Fund increased its holdings in Alphatec by 21.2% in the fourth quarter. New York State Common Retirement Fund now owns 1,202,334 shares of the medical technology company’s stock valued at $11,037,000 after purchasing an additional 210,519 shares during the period. Finally, Walleye Capital LLC raised its position in Alphatec by 3.2% during the 3rd quarter. Walleye Capital LLC now owns 1,061,462 shares of the medical technology company’s stock worth $5,902,000 after purchasing an additional 32,529 shares during the last quarter. 66.35% of the stock is currently owned by institutional investors and hedge funds.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.